title: Why has active immunotherapy not worked in lung cancer?
abstract: Vaccines that rely on active specific stimulation of the host immune system have the potential to trigger durable antitumor responses with minimal toxicity. However, in nonsmall-cell lung cancer (NSCLC), several large phase III trials of vaccines reported within the last year have yielded disappointing results. Compared with placebo, belagenpumatucel-L (an allogenic tumor cell vaccine), tecemotide (a peptide vaccine targeting MUC-1) and melanoma-associated antigen-A3 (a protein-based vaccine) did not improve outcomes in NSCLC. The lack of clinically significant outcomes, despite their ability to prime and expand tumor antigen-specific T cells could at least partly be attributed to the inability of vaccine-induced T-cell responses to overcome the tumoral mechanisms of immune escape which limit the clonal expansion of T cells following vaccination. A number of such mechanisms have been recognized including reduced antigen presentation, antigenic loss, cytokines, immunosuppressive cells and immune checkpoints. Strategies aimed at modulating the immune checkpoints have shown promise and are on the verge of revolutionizing the therapeutic landscape of metastatic NSCLC. Overcoming immune tolerance and improving the activation of antitumor T cells via combinatorial approaches may represent a new and more promising therapeutic application for active immunotherapies in NSCLC.
authors.affiliation: Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda.
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA gg496@georgetown.edu.
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends; D008175:Lung Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm
keywords: active immunotherapy; immune checkpoint; nonsmall-cell lung cancer; tumor-mediated immunosuppression; vaccines